DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Acetaminophen's Antinociceptive Effect When Associated With N-Acetylcysteneine

Information source: University Hospital, Clermont-Ferrand
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: N-acetylcysteine combination with acetaminophen (Drug); Placebo (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: University Hospital, Clermont-Ferrand

Official(s) and/or principal investigator(s):
Gisèle PICKERING, Principal Investigator, Affiliation: University Hospital, Clermont-Ferrand

Overall contact:
Patrick LACARIN, Phone: 04 73 75 11 95, Email: placarin@chu-clermontferrand.fr

Summary

Acetaminophen is one of the most widely used analgesic in the world, recommended for the symptomatic treatment of fever and pain. The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine. The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine

1. - decrease the antinociceptive effect of acetaminophen in comparison to a group control

2. - and if this antinociceptive effect may depend of the genetic polymorphism of GSH

enzyme.

Clinical Details

Official title: ACETAMINOPHEN ANTINOCICEPTIVE EFFECT WHEN ASSOCIATED WITH N-ACETYLCYSTENEINE

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Pain intensity using Visual Analog Scales (VAS) succeeding thermic stimulations at the threshold temperature +3°C before (T0-1h) and after acetaminophen's administration

Secondary outcome:

Blood glutathione GSH concentration

Blood of acetaminophen concentration and its metabolites

Urinary assay of the rate of acetaminophen and its metabolites

Pharmacogenetic dosage of enzymes involved in glutathione metabolism

Detailed description:

Period 1 : To Day - 4 to Day 0

Day - 4 at 8: 00 am at Clinical Pharmacology Center

- Inclusion Visit, signature of Informed consent form, clinical exam.

- Training test

- Blood sample (GSH, pharmacogenetic, Biochemistry assay)

- Randomization and attribution of treatment for the fisrt study period at home: (day -4,

- 3, -2, -1) 4 days of oral acetaminophen and [N-acetylcysteine or placebo] according

to the randomization plan.

At day - 3, -2 and -1 a salivary sample will be done to control the treatment compliance.

Day 0 at Clinical Pharmacology Center Clinical examination Measurement of the basal pain thresholds and pain evaluation (Visual Analog Scales) Blood and urinary sample (acetaminophen and GSH assay) T0 : Administration of product: acetaminophen and [N-acetylcysteine or placebo] T0+1H: Thermal stimulation according to the established paradigm (threshold temperature +3°C ) and pain evaluation (Visual Analog Scales) T0+2H: Thermal stimulation according to the established paradigm (threshold temperature +3°C ) and pain evaluation (Visual Analog Scales) and Blood sample (acetaminophen assay) T0+3H: Thermal stimulation according to the established paradigm (threshold temperature +3°C ) and pain evaluation (Visual Analog Scales) T0+4H: Thermal stimulation according to the established paradigm (threshold temperature +3°C ) and pain evaluation (Visual Analog Scales) and Blood and urinary sample (acetaminophen, GSH, biochemistry assay)

- Lunch before departure

2 weeks of wash-out Period 2 : To Day 17 to Day 21 Same of period 1. Subject who receives N-acétylcystéine in period 1 will receive placebo in second period and vice versa.

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Male

- Between 18 and 45 years old

- Without treatment during the 7 days before inclusion specially no use of antalgic and

anti-inflammatory

- Cooperation and understanding enough to conform to the study obligations -Having

given free, informed written consent

- Affiliated at system of French social security

- Inscription or acceptation of inscription in the national register of volunteers

involved in trials. Exclusion Criteria:

- Patient with one or many contraindication for the administration of the trial's

products,

- Patient that have taken N-acetylcysteine as bronchial thinner during the last 3 days,

- Patient with medical or surgical history judged by the investigator or his

representative as being not compatible with the clinical trial

- Patient with disease progression during inclusion,

- Patient with excessive consumption of alcohol, tobacco (+ than 10 cigarette/day),

coffee, tea or drinks with caffeine (equivalent to more than 4 cup a day) or any addiction to drugs,

- Patient with a heat pain mean threshold during training higher or equal to 46. 5°C,

- Patient who participated in another clinical trial, located in exclusion period or

received benefits > 4500 euros during 12 months before the beginning of trial,

- Patient with cooperation and understanding that do not allow him to follow the trial,

- Patients with minor or under guardianship,

- No affiliation at system of French social security

Locations and Contacts

Patrick LACARIN, Phone: 04 73 75 11 95, Email: placarin@chu-clermontferrand.fr

CHU de Clermont-Ferrand, Clermont-Ferrand 63003, France; Recruiting
Patrick LACARIN, Phone: 04 73 75 11 95, Email: placarin@chu-clermontferrand.fr
Additional Information

Starting date: September 2013
Last updated: July 31, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017